References
- Diabetes: facts and figures [internet]. Belgium: Inter-national Diabetes Federation; 2015 [cited 2016 Aug 14]. Available from: http://www.idf.org/about-diabetes/facts-figures.
- Kabadi UM. Sulfonylurea glimepiride: a proven cost effective, safe and reliable war horse in combating hyperglycemia in type 2 diabetes. J Diabetes Mellitus. 2015;5(4):211-26. https://doi.org/10.4236/jdm.2015.54026
- Pemminati S, Millis RM, Kamath A, Shenoy AK, Gan-gachannaiah S. Are the newer antidiabetic agents worth the cost?. J Clin Diagn Res. 2016;10(3):DOI: 10.7860/JCDR/2016/17683.7384.
- Zhang Y, McCoy RG, Mason JE, Smith SA, Shah ND, Denton BT. Second-line agents for glycemic control for type 2 diabetes: are newer agents better?. Diabetes Care. 2014;37(5):1338-45. https://doi.org/10.2337/dc13-1901
- Chowdhary M, Kabbani AA, Chhabra A. Canaglifloz-in-induced pancreatitis: a rare side effect of a new drug. Ther Clin Risk Manag. 2015;11:991-4.
- Pemminati S, Adhikari P, Pai MR, Pathak R. Metabolic syndrome among inmates of a 'home for aged' using IDF 2005 criteria. Nepal Med Coll J. 2009;11(1):31-3.
- Pemminati S, Prabha Adhikari MR, Pathak R, Pai MR. Prevalence of metabolic syndrome (METS) using IDF 2005 guidelines in a semi urban south Indian (boloor diabetes study) population of Mangalore. J Assoc Physicians India. 2010;58:674-7.
- Guettier JM, Georgopoulos A, Tsai MY, Radha V, Shan-thirani S, Deepa R, et al. Polymorphisms in the fatty ac-id-binding protein 2 and apolipotrotein C-III genes are associated with the metabolic syndrome and dyslipi-demia in a South Indian population. J Clin Endocrinol Metab. 2005;90(3):1705-11. https://doi.org/10.1210/jc.2004-1338